Exploring High Growth Tech Stocks in the UK for October 2024
In This Article:
The UK market has recently faced challenges, with the FTSE 100 index experiencing a downturn due to weak trade data from China and concerns over global economic recovery. In this environment, identifying high growth tech stocks requires focusing on companies that can demonstrate resilience and innovation despite broader market pressures.
Top 10 High Growth Tech Companies In The United Kingdom
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| STV Group | 13.15% | 46.78% | ★★★★★☆ |
| Gaming Realms | 11.57% | 22.07% | ★★★★★☆ |
| YouGov | 14.29% | 29.79% | ★★★★★☆ |
| Facilities by ADF | 52.00% | 144.70% | ★★★★★☆ |
| Redcentric | 4.89% | 63.79% | ★★★★★☆ |
| Windar Photonics | 63.60% | 126.92% | ★★★★★☆ |
| LungLife AI | 100.61% | 100.97% | ★★★★★☆ |
| Beeks Financial Cloud Group | 24.63% | 57.95% | ★★★★★☆ |
| Oxford Biomedica | 20.98% | 106.13% | ★★★★★☆ |
| Vinanz | 113.60% | 125.86% | ★★★★★☆ |
Click here to see the full list of 46 stocks from our UK High Growth Tech and AI Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Genus
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Genus plc is an animal genetics company with operations across North America, Latin America, the United Kingdom, Europe, the Middle East, Russia, Africa, and Asia and has a market cap of ￡1.33 billion.
Operations: Genus plc generates revenue primarily through its two main segments: Genus ABS, which contributes ￡314.90 million, and Genus PIC, bringing in ￡352.50 million. The company's operations span multiple regions globally, focusing on animal genetics to drive its business model.
Genus plc, facing a challenging year with a significant one-off loss of ￡47.4M, still manages to project an impressive earnings growth trajectory at 39.4% annually, outpacing the UK market's 14.3%. Despite this robust forecast and maintaining last year's dividend rate at 21.7 pence per share, its recent financial performance reveals a contraction with sales dipping to ￡668.8 million from ￡689.7 million and net income falling to ￡7.9 million from ￡33.3 million previously. This juxtaposition of strong growth prospects against current financial setbacks highlights the volatile yet potentially rewarding nature of investing in high-growth tech sectors like biotechnology where Genus operates.
-
Navigate through the intricacies of Genus with our comprehensive health report here.
-
Explore historical data to track Genus' performance over time in our Past section.
NCC Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: NCC Group plc operates in the cyber and software resilience sector across the United Kingdom, Asia-Pacific, North America, and Europe with a market cap of ￡537.09 million.
Operations: NCC Group plc derives its revenue primarily from Cyber Security (￡258.50 million) and Escode (￡65.90 million). The company's focus on cyber and software resilience spans multiple regions, including the United Kingdom, Asia-Pacific, North America, and Europe.